A Hepatocellular Carcinoma Patient with TSC1 Mutations Benefits from Treatment with Everolimus: A Case Report
Open Access
- 27 May 2020
- journal article
- case report
- Published by S. Karger AG in Visceral Medicine
- Vol. 37 (2) , 116-119
Abstract
Hepatocellular carcinoma (HCC) has a high degree of malignancy and poor prognosis. Treatment options for patients with advanced HCC are limited. There is currently no evidence to approve the accumulation of targeted therapies for HCC to support the inhibition of the PI3K/Akt/mTOR signaling pathway as an effective therapeutic strategy. We report on a patient with advanced HCC carrying the TSC1 gene mutation who responded well to the mammalian target of rapamycin inhibitor everolimus. Computed tomography revealed tumor shrinkage and maintenance of partial remission after everolimus treatment for >12.3 months. To the best of our knowledge, this is the first clinical case report showing benefit from everolimus treatment in HCC patients with TSC1 gene mutations. Therefore, everolimus may be used as a potential targeted therapy for HCC with TSC1 gene mutation.Keywords
This publication has 22 references indexed in Scilit:
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- Frequency of TERT promoter mutations in human cancersNature Communications, 2013
- Highly Recurrent TERT Promoter Mutations in Human MelanomaScience, 2013
- TERT Promoter Mutations in Familial and Sporadic MelanomaScience, 2013
- Genome Sequencing Identifies a Basis for Everolimus SensitivityScience, 2012
- Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case reportJournal of Medical Case Reports, 2012
- High-resolution characterization of a hepatocellular carcinoma genomeNature Genetics, 2011
- The Phosphoinositide 3-Kinase Regulatory Subunit p85α Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor SignalingCancer Research, 2010
- The retinoblastoma tumor-suppressor gene, the exception that proves the ruleOncogene, 2006
- Rheb is a direct target of the tuberous sclerosis tumour suppressor proteinsNature Cell Biology, 2003